









Markets
/
Stocks
/
nasdaq-traw
/

Traws Pharma Inc

TRAW

View Detailed Chart

1.490USD

+0.030+2.05%

Market hours （ET）Quotes delayed by 15 min

7.56MMarket Cap

LossP/E TTM



Traws Pharma Inc

1.490

+0.030+2.05%

Overview Company Financials

Financials

Intraday

30m

Today

+2.05%

5 Days

-5.70%

1 Month

+2.76%

6 Months

-80.11%

Year to Date

-83.22%

1 Year

-83.59%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(8)

Neutral(2)

Buy(0)

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.025

Neutral

RSI(14)

42.607

Neutral

STOCH(KDJ)(9,3,3)

8.219

Oversold

ATR(14)

0.092

Low Volatility

CCI(14)

-159.602

Sell

Williams %R

100.000

Oversold

TRIX(12,20)

0.117

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.536

Sell

MA10

1.584

Sell

MA20

1.565

Sell

MA50

1.549

Sell

MA100

1.748

Sell

MA200

3.777

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

Ticker SymbolTRAW

CompanyTraws Pharma Inc

CEODr. Iain D. Dukes, Ph.D.

Websitehttps://www.onconova.com/